Ovarian Cancer Patients Survive Longer with BRCA2 Mutated in Tumors
Tuesday, October 11, 2011 - 17:00
in Health & Medicine
Women with high-grade ovarian cancer live longer and respond better to platinum-based chemotherapy when their tumors have BRCA2 genetic mutations, researchers at The University of Texas MD Anderson Cancer Center and the Institute for Systems Biology report in the Oct. 12 issue of the Journal of the American Medical Association.